- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
UBE2G1 Antibody (C-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP2121b | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
UBE2G1 Antibody (C-term) Blocking Peptide - Product info | |
| Primary Accession | P62253 |
| Other Accession | NP_003333 |
| Clone Names | 3061807 |
| Calculated MW | 19509 Da |
UBE2G1 Antibody (C-term) Blocking Peptide - Additional info | |
| Gene ID 7326 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP2121b was selected from the C-term region of human UBE2G1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
UBE2G1 Antibody (C-term) Blocking Peptide - Protein Information | |
| Name UBE2G1 | |
| Synonyms UBE2G | |
| Function Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys- 48'-, as well as 'Lys-63'-linked polyubiquitination. May be involved in degradation of muscle-specific proteins. Mediates polyubiquitination of CYP3A4 | |
| Tissue Location Widely expressed, mainly in skeletal muscle. | |
UBE2G1 Antibody (C-term) Blocking Peptide - Related products
AP2121a: UBE2G1 Antibody (N-term)
AP2121b: UBE2G1 Antibody (C-term)
RI15575: UBE2G1 predesign siRNA
LY10557a: UBE2G1 Over-expression Lysate
BP2121a: UBE2G1 Antibody (N-term) Blocking Peptide
UBE2G1 Antibody (C-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. UBE2G1 is a member of the E2 ubiquitin-conjugating enzyme family. The encoded protein shares 98-100% sequence identity with the zebrafish, frog, rat and mouse counterparts, which indicates that this enzyme is highly conserved in eukaryotes.
REFERENCES
Watanabe, T.K., et al., Cytogenet. Cell Genet. 74 (1-2), 146-148 (1996).